And importantly, we know that it's important to engage a broader prescriber base who are treating that 7,500 moderate to severe ISM patients who are diagnosed and actively seeking treatment today.

Source: https://seekingalpha.com/article/4579168-blueprint-medicines-corporation-bpmc-q4-2022-earnings-call-transcript?source=feed_all_articles

However, none of these entries had been signed by a medical or nurse prescriber, as is required in accordance with Royal College of Nursing guidance.

Source: https://www.gazettelive.co.uk/news/teesside-news/clinic-special-measures-after-damning-27325118

Our LytaLink patient and prescriber support program continues to be very effective in supporting patient access to CAPLYTA.

Source: https://forextv.com/top-news/intra-cellular-therapies-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-corporate-update/